6 Review of guidance

6 Review of guidance

6.1 The guidance on this technology will be considered for review at the same time as NICE technology appraisal guidanceĀ 178 and 219 for the secondā€‘line treatment of advanced renal cell carcinoma.

Andrew Dillon
Chief Executive
February 2015

  • National Institute for Health and Care Excellence (NICE)